Judith Kelleher-Andersson, Ph.D.
Founder, President and Chief Executive Officer (CEO)
"A therapy that is only neuroprotective will never be sufficient to halt or reverse neurodegenerative disease progression." I came to this realization after working in the neuroscience field for over 20 years as a graduate student, as a post-graduate fellow and after working at three biotech companies, where I directed the discovery of therapeutics aimed at Alzheimer's disease and other neurodegenerative disorders.
Read full message...
Neuronascent, Inc. (NNI) has discovered and is developing therapies for depression, Down syndrome, post-traumatic stress disorder, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. Our lead candidate for Alzheimer’s disease (AD), NNI-362 has shown great promise in several disease models, with no sign of toxicity or other harmful effects. NNI-362, a small molecule agent promotes new neuron growth in the hippocampus of aged and Down syndrome animal models, a region of the brain where neurons are significantly lost in AD ultimately causing cognitive decline -- a hallmark of the disease. This replacement of neurons lost or reduced, in the hippocampus, along with actual reversal in cognitive deficit in animal models suggests this agent could be neuro-regenerative for AD patients as well. The National Institute on Aging is presently supporting IND safety studies following completion of a pre-IND meeting with the FDA (May 2014).
Each of NNI’s small-molecule, lead therapeutic candidates promote new neurons from the brain’s own neuronal progenitor cell populations in culture and animal models. The candidates have been optimized to increase neuron numbers in the brain, to improve critical function and to diminish loss of neurons due to disease progression. This ensures that each therapeutic candidate is optimal for a disease indication. In fact, NNI’s depression and post-traumatic stress disorder therapy, NNI-351 is chemically and functionally different than NNI’s neurodegenerative therapeutic, NNI-362, with the former promoting the earliest steps of neurogenesis, while NNI-362 mostly notably promotes the later steps of the neurogenesis process resulting in a neuro-regenerative therapeutic candidate.
Please read on to learn more about the field of neurogenesis and learn how Neuronascent’s lead therapeutics are aimed at disease indications with some of the greatest unmet patient need.
NEWS & EVENTS
Apr 2015 Neuronascent Secures Financing for Development of Its Alzheimer's Therapeutic. View Press Release
Feb 2015 Neuronascent Announces Expanded Patent Coverage In US and Russia For Its Alzheimer's Disease and Down Syndrome Therapeutics. View Press Release
Sep 2014 NI Research’s September 2014 Issue of NeuroPerspective fully reviews Alzheimer’s therapeutics and prominently mentions Neuronascent, Inc. In covering the different approaches to Alzheimer’s therapeutic development, the review notes that “The one neurogenesis-focused company prioritizing Alzheimer’s is Neuronascent.” Click to purchase and download the full issue. NeuroPerspective publisher Dr. Harry Tracy also called Neuronascent “the neurogenesis specialist,” and he selected Neuronascent’s program as one of the ‘Top Ten’ CNS partnering opportunities to be presented at the Informa Therapeutic Area Partnerships conference, which will be held in Boston this November.
Apr 2014 Neuronascent Successfully Completes Pre-IND Meeting with FDA for Alzheimer’s Disease Therapeutic.
View Press Release